Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Heva Health vs Maves

Heva Health
Graded #114

Lower grade

vs+2.0999999999999943
Maves
Graded #89

Higher grade

The verdict

Maves takes it — 71.8/100 to 69.7/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +10
74
84
Dose & formulationMaves +13
52
65
Clinical oversightMaves +2
74
76
Labs & monitoringHeva Health +37
89
52
FulfillmentMaves +18
69
87
Contract termsEven
55
55
Heva Health · left barMaves · right bar

The numbers

MetricHeva HealthMaves
WeighScore69.7/10071.8/100
GradeCC
Scorecard rank#114#89
Semaglutide$149/mo (compounded)$99/mo (starting dose, first-month rate, compounded)
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Heva Health

Graded #114 · C

Strengths

  • $149/mo entry pricing for compounded GLP-1 is competitive
  • LegitScript Certified
  • Claims licensure in all 50 states
  • Comprehensive 91-biomarker lab panel bundled — a differentiator vs compounded-GLP-1-only peers
  • Concierge care plus HRT/TRT alongside GLP-1 for an integrated longevity stack

Where it loses points

  • Tirzepatide pricing not shown — only the generic $149/mo weight-loss entry
  • Legal entity name and state of incorporation not disclosed
  • Partner pharmacy not named
  • Per-state availability not listed despite the all-50-states claim
  • Brand-name GLP-1 options (Wegovy/Zepbound/Mounjaro/Ozempic/Foundayo) not addressed
Maves

Graded #89 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard